期刊文献+

用蛋白芯片技术检测幽门螺杆菌抗体在临床上的应用 被引量:4

Clinical application of helicobacter plylori antibody detected with protein chip technology
原文传递
导出
摘要 目的:通过检测幽门螺杆菌(HP)患者血清中细胞毒素相关蛋白(CagA)、尿素酶(UreC)、热休克蛋白(HSP60)的抗体谱,探讨HP感染的消化道疾病患者在不同年龄组的分布及种类的差异。方法:采用蛋白芯片方法对457例临床患者HP血清进行检测。结果:检测出HP阳性率为89.72%,高于广州地区(63.1%),其中老年组检测率最高为91.59%。老年组UreC抗体阳性率为74.30%,高于儿童组和青年组,差异有统计学意义。CagA、UreC感染的毒力株以青年组为主,高于儿童组和老年组。结论:提示HP感染的青年组以UreC、Ca-gA为主,老年组以UreC和UreC、HSP60为主。通过筛查不同的抗体类型,可为临床诊断治疗消化道疾病提供重要的指导意义。 Objective:To investigate the distribution and type of helicobacter plylori(HP) infection during patients with diseases of digestive tract through detecting antibodies of CagA, UreC and HSP60. Method:The helicobacter pylorus (HP)457 clinical examples were detected by protein chip. Result:The HP positive rate was 89.72%, which was higher than that in Guangzhou(63.1%). The HP positive rate of older age group was 91.59%, highest. The positive rate of UreC antibodies of older age group was 74.3%, which was significantly higher than that of children group and young group. There was more CagA and UreC infection induced by virulent isolates in young group than that in children group and older age group. Conclusion:The HP infection type in the young people was mainly UreC and CagA, while in older age group was mainly UreC and HSP60. It might provide an important guidance for the clinical diagnosis and treatment of digestive tract diseases by screening different types of antibodies.
出处 《临床血液学杂志(输血与检验)》 CAS 2011年第4期448-450,共3页 Journal of Clinical Hematology(Blood Transfusion & Laboratory Medicine)
关键词 蛋白芯片 幽门螺杆菌 细胞毒素相关蛋白抗体 尿素酶抗体 热休克蛋白抗体 protein chip helicobacter plylori CagA antibodies UreC antibodies HSP60 antibodies
  • 相关文献

参考文献7

二级参考文献37

  • 1冯丽英,白文元,姚希贤.灭Hp胶囊与新三联并用对溃疡愈合质量及溃疡复发的影响[J].中国全科医学,2004,7(20):1469-1471. 被引量:16
  • 2Garrido SA, Lepe JA, Guerrero IF, et al.Helicobacter pylori and gastroesophageal reflux disease[J].Rev Esp Enferm Dig,2003,95(11):788-790. 被引量:1
  • 3Sarnelli G, Ierardi E, Grasso R, et al.Acid exposure and altered acid clearance in GERD patients treated for Helicobacter pylori infection[J].Dig-Liver-Dis.2003,35(3):151-156. 被引量:1
  • 4Sullivan T, Ashbury FD, Fallone CA, et al.Helicobacter pylori and the prevention of gastric cancer[J].Can J Gastroenterol,2004,18(5):295-302. 被引量:1
  • 5Montalban C, Santon A, Boixeda D, et al.Regression of gastric high grade mucosa associated lymphoid tissue (MALT) lymphoma after Helicobacter pylori eradication[J].Gut, 2001,49(4):584-587. 被引量:1
  • 6Dierkes J, Ebert M, Malfertheiner P, et al.Helicobacter pylori infection, vitamin B12 and homocysteine.A review[J].Dig Dis,2003, 21(3):237-244. 被引量:1
  • 7Cremonini F, Gabrielli M, Gasbarrini G, et al.The relationship between chronic H.pylori infection, CagA seropositivity and stroke:meta-analysis[J].Atherosclerosis,2004,173(2):253-259. 被引量:1
  • 8Markus HS, Mendall MA.Helicobacter pylori infection:a risk factor for ischaemic cerebrovascular disease and carotid atheroma[J].J Neurol Neurosurg Psychiatry, 1998,64(1):104-107. 被引量:1
  • 9Gasbarrini A, De LA, Fiore G, et al.Beneficial effects of Helicobacter pylori eradication on migraine[J].Hepatogastroenterology, 1998,45(21):765-770. 被引量:1
  • 10Gasbarrini A, Massari I, Serricchio M, et al.Helicobacter pylori eradication ameliorates primary Raynaud's phenomenon[J].Dig Dis Sci, 1998,43(8):1641-1645. 被引量:1

共引文献55

同被引文献103

引证文献4

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部